Drugs / Polyethylene Glycol plus Ascorbic Acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT07206329 | Jan 2024 → Jun 2025 | — | Unidade Local de Saúde do Alto Ave, EPE | Completed | Mixed |
| Comparator or background therapy1 trial | ||||||
| — | NCT03247452 Background | Dec 2017 → Mar 2018 | — | Hospital Universitario de Canarias | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polyethylene Glycol plus Ascorbic Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07206329 ↗ |
| Known as | PEG-Asc | “Polyethylene Glycol plus Ascorbic Acid (PEG-Asc)” NCT07206329 ↗ |
| Route | Oral | “patients ingested 1 L solution consisting of 500 mL PEG-Asc taken over one hour” NCT07206329 ↗ |